Study 13 of 29Tirzepatide literatureBMJ (Clinical research ed.)Top journal2026
Tirzepatide and cardiovascular outcomes.
Not reported in abstract.
Where it sits
this study against the rest of the tirzepatide corpus3
Preclinical · this one
19
Observational
1
Open-label
3
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Tirzepatide corpus
B12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obesity pillars · 2026 · n=249 · Mean weight loss was 19.9 ± 8.6% at 12 months.HumanBReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nature medicine · 2026 · Mean weight reduction was 16.1 kg (95% CI 15.9 to 16.2; P < 0.001).HumanAEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obesity pillars · 2026 · Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.HumanBQuantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling.The Journal of clinical endocrinology and metabolism · 2026 · Not reported in abstract.HumanDEstimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.Diabetes care · 2026 · HR 0.72; 95% CI 0.55, 0.94 for MACE-3 comparing tirzepatide versus placebo.reviewBDual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplastybiorxiv-preprint · 2026 · At 2 years, tirzepatide exposure was associated with lower odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96).Human